The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines (Lundbeck)

European Commission fines Lundbeck and other pharmaceutical companies for delaying market entry of generic medicines* On 19 June 2013 the European Commission issued a press release stating that it had imposed fines in the amount of € 93,8 million on Lundbeck (a Danish pharmaceutical company) and € 52,2 million on manufacturers of other generic medicines that were producing a cheaper and generic version of Lundbeck’s brand-drug citalopram.

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Gabriele Accardo, Anthony Reda, The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines (Lundbeck), 19 juin 2013, e-Competitions June 2013, Art. N° 57743

Visites 389

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues